Australian Biotech

Health Minister Mark Butler and his key officials are focused on the potential of artificial intelligence to support decision-making, but New Zealand might currently be ahead.

The challenge is that advisory committees have been allowed to move increasingly into what are policy matters historically left to the minister and the parliament. The invitation to respond to the HTA Review was a natural consequence of this increasing role in policy matters. It was a bad idea that put the committees in a difficult position.

Eli Lilly Australia and Monash University have announced a new healthcare initiative aimed at transforming the management of obesity.

According to Matt Zeller, the Country President of Novartis Australia and New Zealand, the launch reflects HCPs' calls for easier, faster, and simpler access to Novartis’ portfolio of private prescriptions.

“Her pioneering work in human metabolism and diabetes laid the foundations for Novo Nordisk’s commitment to improving the lives of people with serious chronic diseases through science,” said the company's Dr Ana Svensson.

The analysis reveals how the committee's decision-making has evolved over the past decade without any transparent policy framework, industry agreement, or reform of its statutory decision-making framework.

A. Menarini has announced the appointment of its current Commercial Lead, Kelly Turner, as its new General Manager for Australia and New Zealand.

Lilly's announcement that it will increase the private price of MOUNJARO (tirzepatide) in the UK, while its NHS price remains unchanged, highlights the challenge facing any global push on pharmaceutical pricing.

“Australia and New Zealand are priority locations for BeOne’s global clinical development efforts, thanks to their established research networks and internationally respected trial infrastructure,” said Adam Roach, Senior Vice President and Head of Japan and Asia Pacific.

EMVision Medical Devices (ASX: EMV) has secured a significant boost in its mission to transform stroke care, with the Australian Government awarding the company $3 million in non-dilutive funding under the Cooperative Research Centres Projects Round 17 grant program.

The US FDA has informed Neurizon Therapeutics (ASX:NUZ) that a decision on its Clinical Hold Complete Response for the company's lead investigational therapy NUZ-001 is now not expected until 3 October 2025.

For decades, scientists puzzled over whether the tiny chemical tags that cling to our DNA were simply genetic clutter or something far more powerful. These tags, called methyl groups, were often dismissed as the cobwebs of the genome and harmless reminders of genes no longer in use.